15.83
-0.49(-3.00%)
Currency In USD
| Previous Close | 16.32 |
| Open | 16.15 |
| Day High | 16.29 |
| Day Low | 15.37 |
| 52-Week High | 35.25 |
| 52-Week Low | 13.53 |
| Volume | 2.29M |
| Average Volume | 2.39M |
| Market Cap | 1.59B |
| PE | -3.43 |
| EPS | -4.61 |
| Moving Average 50 Days | 18.32 |
| Moving Average 200 Days | 23.96 |
| Change | -0.49 |
If you invested $1000 in Beam Therapeutics Inc. (BEAM) since IPO date, it would be worth $844.27 as of June 01, 2025 at a share price of $15.83. Whereas If you bought $1000 worth of Beam Therapeutics Inc. (BEAM) shares 3 years ago, it would be worth $465.18 as of June 01, 2025 at a share price of $15.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire Inc.
May 29, 2025 8:01 PM GMT
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administratio
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
GlobeNewswire Inc.
May 14, 2025 1:30 PM GMT
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mas
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire Inc.
May 13, 2025 11:00 AM GMT
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at th